Carbinoxamine

Allergic conditions.

Adult: PO As immediate-release tab/soln: 4-8 mg 3-4 times/day. As extended-release susp: 6-16 mg 12 hrly.

Should be taken with food.

Concomitant use w/ MAOIs. Childn <2 yr. Lactation.

Patient w/ asthma, increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, CV disease, HTN, stenosing peptic ulcer, prostatic hypertrophy, bladder neck and pyloroduodenal obstructions. Elderly. Pregnancy. Patient Counselling This drug may cause drowsiness and impaired mental or physical ability, if affected, do not drive or operate machinery.

Urticaria, rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dry mouth, nose, and throat; epigastric distress, anorexia, nausea, vomiting, diarrhoea, constipation; hypotension, headache, palpitations, tachycardia, extrasystoles; fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paraesthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsion, sedation, drowsiness, dizziness, disturbed coordination; increased uric acid levels; chest tightness, wheezing, nasal stuffiness, thickening of bronchial secretions; urinary frequency, difficult urination, urinary retention, early menses; haemolytic anaemia, thrombocytopenia, agranulocytosis.

May increase the effect of other antihistamines, barbiturates, TCAs, and CNS depressants (e.g. hypnotics, sedatives, tranquilisers).

Antihistamines & Antiallergics

R06AA08 - carbinoxamine ; Belongs to the class of aminoalkyl ethers used as systemic antihistamines.